



22 July 2020

Sydney, Australia

Receipt of cash payment for collateral shares

Key points:

- **Receipt of \$129,764 cash in relation to the remaining 0.811 million collateral shares**
- **All collateral share liability now fully paid by lenders**

Sydney, 22 July 2020: Noxopharm (ASX: NOX) wishes to advise that it has received a cash payment of \$129,764 in relation to the remaining portion of the collateral shares that Noxopharm previously issued under the historical convertible security agreements with Lind Partners, LLC and CST Investment Funds (the **Lenders**). These agreements were terminated, as announced by the company on 14 February 2020.

Noxopharm previously issued 4.50 million ordinary shares in aggregate to the Lenders as collateral shares under the convertible security agreements (2.25 million shares per Lender).

The Lenders are required, by 20 December 2021, to pay to Noxopharm in cash the collateralisation price for the outstanding collateral shares. The collateralisation price per collateral share is the lower of:

- 90% of the average of the 5 lowest daily VWAPs of NOX shares during the 20-trading day period prior to the date immediately prior to the payment date; and
- \$0.477.

As announced on 20 April 2020, Noxopharm received total cash payments of \$409,477 in relation to 3,688,978 collateral shares as detailed below:

- \$159,727 from CST Investment Funds in relation to 1,438,978 collateral shares, at a collateralisation price of 11.1 cents per collateral share, reducing the CST Investment Funds outstanding collateral share liability from 2.25 million collateral shares to 811,022; and
- \$249,750 from Lind Partners, LLC in relation to 2,250,000 collateral shares reducing the Lind Partners, LLC outstanding collateral share liability from 2.25 million collateral shares to zero.

On 21 July 2020, Noxopharm received a cash payment of \$129,764 from CST Investment Funds for the remaining 811,022 collateral shares, at a collateralisation price of 16.0 cents per collateral share calculated according to the pricing structure outlined above.



Following this payment, all collateral shares with the Lenders are now fully paid and the Company's obligations under these arrangements have been completed.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in U.S. biotechnology company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Graham Kelly, CEO and Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.